Casdin Capital’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,000,000
| Closed | -$14.2M | – | 39 |
|
|
2025
Q1 | $14.2M | Hold |
2,000,000
| – | – | 1.16% | 16 |
|
|
2024
Q4 | $23.3M | Hold |
2,000,000
| – | – | 1.55% | 15 |
|
|
2024
Q3 | $41.1M | Hold |
2,000,000
| – | – | 2.74% | 11 |
|
|
2024
Q2 | $44.8M | Buy |
2,000,000
+125,000
| +7% | +$2.8M | 3.42% | 9 |
|
|
2024
Q1 | $51.6M | Buy |
1,875,000
+425,000
| +29% | +$11.7M | 3.83% | 8 |
|
|
2023
Q4 | $44.2M | Buy |
1,450,000
+271,925
| +23% | +$8.29M | 4.34% | 6 |
|
|
2023
Q3 | $37.3M | Sell |
1,178,075
-96,925
| -8% | -$3.06M | 4.12% | 8 |
|
|
2023
Q2 | $52M | Hold |
1,275,000
| – | – | 4.54% | 6 |
|
|
2023
Q1 | $47.5M | Buy |
1,275,000
+980,000
| +332% | +$36.5M | 3.91% | 7 |
|
|
2022
Q4 | $10.3M | Hold |
295,000
| – | – | 0.8% | 30 |
|
|
2022
Q3 | $16.5M | Buy |
+295,000
| New | +$16.5M | 1.08% | 19 |
|